Welcome to CDC Stacks | Updated Recommendations from the Advisory Committee on Immunization Practices (ACIP) for Use of Hepatitis A Vaccine in Close Contacts of newly Arriving International Adoptees - 7331 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Updated Recommendations from the Advisory Committee on Immunization Practices (ACIP) for Use of Hepatitis A Vaccine in Close Contacts of newly Arriving International Adoptees
  • Status:
    current
  • Source:
    MMWR. Morbidity and mortality weekly report. 2009; 58(36):1006-7.
Filetype[PDF - 1.78 MB]


Details:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. Update: Prevention of Hepatitis A after Exposure to Hepatitis A Virus and in International Travelers. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Corporate Author:
    Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
    Source:
    MMWR. Morbidity and mortality weekly report. 2007; 56(41):1080-4.
    Description:
    This report updates and consolidates all previous U.S. Public Health Service recommendations for the management of health-care personnel (HCP) who have occupational exposure to blood and other body fluids that might contain hepatitis B virus (HBV), h...
    Status:
    current
    File Type:
    Filetype[PDF - 482.83 KB]
  2. FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP)
    Source:
    MMWR. Morbidity and mortality weekly report. 2010; 59(20):626-9.
    Description:
    On October 16, 2009, the Food and Drug Administration (FDA) licensed bivalent human papillomavirus vaccine (HPV2; Cervarix, GlaxoSmithKline) for use in females aged 10 through 25 years. Cervarix is the second human papillomavirus (HPV) vaccine licens...
    Status:
    current
    File Type:
    Filetype[PDF]
  3. Updated Recommendations for Use of Meningococcal Conjugate Vaccines -- Advisory Committee on Immunization Practices (ACIP), 2010
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.
    Published:
    January 28, 2011
    Source:
    MMWR. Morbidity and mortality weekly report. 2011; 60(3):72-6.
    Description:
    On October 27, 2010, the Advisory Committee on Immunization Practices (ACIP) approved updated recommendations for the use of quadrivalent (serogroups A, C, Y, and W-135) meningococcal conjugate vaccines (Menveo, Novartis; and Menactra, Sanofi Pasteur...
    Status:
    superseded
    File Type:
    Filetype[HTML]
  4. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular ertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having Close Contact with an Infant Aged <12 Months -- Advisory Committee on Immunization Practices (ACIP), 2011
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.
    Published:
    October 21, 2011
    Source:
    MMWR. Morbidity and mortality weekly report. 2011; 60(41):1424-6.
    Description:
    Compared with older children and adults, infants aged <12 months have substantially higher rates of pertussis and the largest burden of pertussis-related deaths. Since 2004, a mean of 3,055 infant pertussis cases with more than 19 deaths has b...
    Status:
    superseded
    File Type:
    Filetype[HTML]
  5. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated.
    Source:
    MMWR. Morbidity and mortality weekly report. 2008; 57(13):343-4.
    Description:
    This notice updates the recommendation for use of 7-valent pneumococcal conjugate vaccine (PCV7) among children aged 24-59 months who are either unvaccinated or who have a lapse in PCV7 administration. In February 2000, PCV7, marketed as Prevnar and ...
    Status:
    superseded
    File Type:
    Filetype[PDF - 319.43 KB]